| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) (NCT01067469) | M.D. Anderson Cancer Center | 2010-01-01 |
| Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma (NCT01004874) | Duke University | 2009-12-30 |
| Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma (NCT01011231) | University of California, San Francisco | 2009-12-01 |
| Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) (NCT00948389) | Bristol-Myers Squibb | 2009-10-01 |
| Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas (NCT00939991) | Katy Peters | 2009-10-01 |
| Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform (NCT00977431) | Boehringer Ingelheim | 2009-09-17 |
| The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function (NCT00973557) | Cedars-Sinai Medical Center | 2009-09-01 |
| Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma (NCT00960492) | Exelixis | 2009-09-01 |
| Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma (NCT01044225) | Bart Neyns | 2009-09-01 |
| Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery (NCT00961090) | Matthew R Quigley | 2009-09-01 |
| Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults (NCT01043536) | Centre Georges Francois Leclerc | 2009-09-01 |
| Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI) (NCT01208909) | University of Zurich | 2009-08-01 |
| A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma (NCT00943826) | Hoffmann-La Roche | 2009-06-29 |
| Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients (NCT01100177) | Grupo Español de Investigación en Neurooncología | 2009-06-01 |
| A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas (NCT00921167) | Clinical Research Center for Solid Tumor, Korea | 2009-06-01 |
| Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma (NCT00895960) | M.D. Anderson Cancer Center | 2009-05-07 |
| Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma (NCT00884741) | National Cancer Institute (NCI) | 2009-04-15 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status (NCT00813943) | EMD Serono | 2009-03-01 |
| Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma (NCT00694837) | Maastricht Radiation Oncology | 2009-03-01 |
| Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients (NCT01345370) | Center Eugene Marquis | 2009-03-01 |
| Sorafenib in Newly Diagnosed High Grade Glioma (NCT00884416) | University Hospital, Geneva | 2009-03-01 |
| O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas (NCT00669669) | Fred Hutchinson Cancer Center | 2009-02-25 |
| Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma (NCT00846456) | Oslo University Hospital | 2009-01-01 |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma (NCT01095094) | Case Comprehensive Cancer Center | 2009-01-01 |
| Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma (NCT00734526) | M.D. Anderson Cancer Center | 2008-12-18 |
| Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea (NCT00807027) | GC Cell Corporation | 2008-12-05 |
| Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma (NCT02599090) | M.D. Anderson Cancer Center | 2008-12-01 |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma (NCT00761280) | Isarna Therapeutics GmbH | 2008-12-01 |
| Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma (NCT00790452) | M.D. Anderson Cancer Center | 2008-11-01 |
| Borderzone Sampling (NCT00780819) | Maastricht University Medical Center | 2008-10-01 |
| Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma (NCT00821080) | Massachusetts General Hospital | 2008-10-01 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (NCT00689221) | EMD Serono | 2008-09-01 |
| A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma (NCT00762255) | H. Lee Moffitt Cancer Center and Research Institute | 2008-09-01 |
| Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer (NCT00693095) | John Sampson | 2008-09-01 |
| Measuring Non-Enhancing Glioblastoma Progression (NCT00777686) | M.D. Anderson Cancer Center | 2008-08-01 |
| Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma (NCT00703859) | AHS Cancer Control Alberta | 2008-07-01 |
| Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma (NCT00687765) | Sanofi | 2008-07-01 |
| Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) (NCT00686725) | Merck Sharp & Dohme LLC | 2008-06-24 |
| Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma (NCT01880008) | Washington University School of Medicine | 2008-04-01 |
| Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors (NCT00667394) | National Cancer Institute (NCI) | 2008-04-01 |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan (NCT00613028) | Duke University | 2008-04-01 |
| Ph I SU011248 + Irinotecan in Treatment of Pts w MG (NCT00611728) | Duke University | 2008-03-01 |
| Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP) (NCT00624728) | University Hospital, Bordeaux | 2008-02-01 |
| Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas (NCT00613223) | Annick Desjardins | 2008-02-01 |
| Ph I Dasatinib + Erlotinib in Recurrent MG (NCT00609999) | Duke University | 2008-01-01 |
| ADV-TK Improves Outcome of Recurrent High-Grade Glioma (NCT00870181) | Huazhong University of Science and Technology | 2008-01-01 |
| Metronomic Temozolamide in Patients With Recurrent Glioblastoma (NCT01308632) | Grupo Español de Investigación en Neurooncología | 2007-11-01 |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma (NCT00613054) | Annick Desjardins | 2007-11-01 |
| Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma (NCT00525525) | University of California, San Francisco | 2007-09-01 |
| Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma (NCT00521482) | University of Zurich | 2007-09-01 |
| Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas (NCT00612339) | Duke University | 2007-08-01 |
| Temozolomide in Elderly Patients With KPS < 70 (NCT01242566) | Assistance Publique - Hôpitaux de Paris | 2007-07-01 |
| Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas (NCT00597402) | Duke University | 2007-07-01 |
| Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma (NCT00576641) | Cedars-Sinai Medical Center | 2007-05-01 |
| Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma (NCT00864864) | Massachusetts General Hospital | 2007-05-01 |
| Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816) (NCT00725010) | Merck Sharp & Dohme LLC | 2007-04-01 |
| Ph II Bevacizumab + Etoposide for Pts w Recurrent MG (NCT00612430) | Duke University | 2007-03-01 |
| A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma (NCT00606008) | H. Lee Moffitt Cancer Center and Research Institute | 2007-03-01 |
| Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) (NCT00671970) | Duke University | 2007-02-01 |
| Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma (NCT01364064) | King Faisal Specialist Hospital & Research Center | 2007-01-01 |
| Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) | Northwest Biotherapeutics | 2006-12-01 |
| URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol (NCT00392548) | Tel-Aviv Sourasky Medical Center | 2006-10-01 |
| Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients (NCT00402116) | Eli Lilly and Company | 2006-09-01 |
| PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs (NCT00385853) | Massachusetts General Hospital | 2006-09-01 |
| Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma (NCT00575887) | Marmara University | 2006-08-01 |
| A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) (NCT00345163) | Genentech, Inc. | 2006-07-01 |
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma (NCT00365222) | H. Lee Moffitt Cancer Center and Research Institute | 2006-07-01 |
| The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) (NCT00392171) | Merck Sharp & Dohme LLC | 2006-06-09 |
| Epothilone in Recurrent Glioblastoma Patients (NCT00397072) | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 2006-06-01 |
| Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739) (NCT00704808) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) (NCT00615927) | Duke University | 2006-02-01 |
| Enzastaurin Versus Lomustine in Glioblastoma (NCT00295815) | Eli Lilly and Company | 2006-01-01 |
| Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide (NCT00616005) | Duke University | 2005-11-01 |
| PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas (NCT00612651) | Duke University | 2005-10-01 |
| Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) (NCT00684567) | Merck Sharp & Dohme LLC | 2005-09-27 |
| Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma (NCT00190424) | Assistance Publique - Hôpitaux de Paris | 2005-09-01 |
| ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors (NCT00132158) | St. Jude Children's Research Hospital | 2005-09-01 |
| Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme (NCT00165477) | Dana-Farber Cancer Institute | 2005-09-01 |
| Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG (NCT00613132) | Annick Desjardins | 2005-05-01 |
| Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma (NCT00354913) | Duke University | 2005-05-01 |
| Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas (NCT00100802) | Children's Oncology Group | 2005-03-21 |
| Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) (NCT00335075) | Merck Sharp & Dohme LLC | 2005-03-02 |
| Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide (NCT00250211) | AHS Cancer Control Alberta | 2005-03-01 |
| Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM (NCT00612989) | Duke University | 2005-02-01 |
| Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly (NCT01502241) | Heidelberg University | 2005-01-01 |
| Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas (NCT00612638) | Duke University | 2005-01-01 |
| Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) (NCT00087451) | Merck Sharp & Dohme LLC | 2004-07-01 |
| Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors (NCT00088400) | National Institute of Neurological Disorders and Stroke (NINDS) | 2004-07-01 |
| Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) (NCT00171938) | Novartis | 2004-04-01 |
| Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas (NCT00074646) | Celgene Corporation | 2003-12-01 |
| Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme (NCT00068952) | Pfizer | 2003-08-01 |
| A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) (NCT00337883) | Genentech, Inc. | 2003-07-01 |
| Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma (NCT00431561) | Isarna Therapeutics GmbH | 2003-04-01 |
| A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme (NCT00238797) | AstraZeneca | 2003-02-01 |
| Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma (NCT00944801) | University of Regensburg | 2002-07-01 |
| Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer (NCT00028158) | MediGene | 2001-12-01 |
| BNCT to Treat Glioma That Has Progressed Following Radiotherapy (NCT00115440) | Boneca Corporation | 2001-03-01 |
| Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors (NCT00576537) | Cedars-Sinai Medical Center | 2001-03-01 |
| Natural History of Patients With Brain and Spinal Cord Tumors (NCT00009035) | National Cancer Institute (NCI) | 2001-01-22 |
| Efficacy of Distant Healing in Glioblastoma Treatment (NCT00029783) | National Center for Complementary and Integrative Health (NCCIH) | 2000-09-01 |